New paediatric acute lymphoblastic leukaemia (ALL) treatments have been developed and innovative products are in the pipeline. However, despite many active clinical trials, bridging bench science to clinical development to authorised medicines remains challenging. Research in first-line treatment continues to focus on multidrug chemotherapy with the potential addition of new targeted molecules being studied. Research in second- and third-line treatment represents a shift from cytotoxic intensification to an area of precision medicine through emergent innovative and immuno-oncology products. The collaborative research model in ALL involving different stakeholders should intensify to facilitate bench-to-bedside clinical translation for the benefit of patients.

Micallef, B., Nistico', R., Sarac, S.b., Bjerrum, O.w., Butler, D., Sammut Bartolo, N., et al. (2022). The changing landscape of treatment options in childhood acute lymphoblastic leukaemia. DRUG DISCOVERY TODAY, 27(5), 1483-1494 [10.1016/j.drudis.2022.01.002].

The changing landscape of treatment options in childhood acute lymphoblastic leukaemia

Nistico' R;
2022-05-01

Abstract

New paediatric acute lymphoblastic leukaemia (ALL) treatments have been developed and innovative products are in the pipeline. However, despite many active clinical trials, bridging bench science to clinical development to authorised medicines remains challenging. Research in first-line treatment continues to focus on multidrug chemotherapy with the potential addition of new targeted molecules being studied. Research in second- and third-line treatment represents a shift from cytotoxic intensification to an area of precision medicine through emergent innovative and immuno-oncology products. The collaborative research model in ALL involving different stakeholders should intensify to facilitate bench-to-bedside clinical translation for the benefit of patients.
mag-2022
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore BIO/14 - FARMACOLOGIA
English
Childhood acute lymphoblastic leukaemia
Clinical drug development
Clinical trials
EU regulation
Oncology
Research
Micallef, B., Nistico', R., Sarac, S.b., Bjerrum, O.w., Butler, D., Sammut Bartolo, N., et al. (2022). The changing landscape of treatment options in childhood acute lymphoblastic leukaemia. DRUG DISCOVERY TODAY, 27(5), 1483-1494 [10.1016/j.drudis.2022.01.002].
Micallef, B; Nistico', R; Sarac, Sb; Bjerrum, Ow; Butler, D; Sammut Bartolo, N; Serracino-Inglott, A; Borg, Jj
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
The changing landscape of treatment options in childhood acute lymphoblastic leukaemia.pdf

solo utenti autorizzati

Descrizione: The changing landscape of treatment options in childhood acute lymphoblastic leukaemia
Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 5.02 MB
Formato Adobe PDF
5.02 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/325444
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact